4D Molecular Therapeutics, Inc., a late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherlands and the United States. Its lead product candidate is 4D-150 for the treatment of retinal vascular diseases by providing multi-year sustained production of anti-VEGF from the retina with intravitreal injection, as well as for treating wet age-related macular degeneration and diabetic macular edema. The company is also developing 4D-710, which is in early-stage study for the treatment of cystic fibrosis; 4D-175 that is in in preclinical stage for treating geographic atrophy; 4D-725, which is in preclinical stage for the treatment of alpha-1 anti-trypsin deficiency lung disease; and 4D-310 that is in Phase 1 clinical trial for treating Fabry disease. 4D Molecular Therapeutics, Inc. has collaboration and licensing agreements with Astellas Gene Therapies, Inc.; Arbor Biotechnologies, Inc.; and uniQure biopharma B.V. The company was founded in 2013 and is headquartered in Emeryville, California.

• Download SqueezeTrigger (TM) Report
• Download FrictionFactor Report
• Download Daily Short Volume Report
• Download Real-Time Short Volume Tool
• Download Failures to Deliver

• [08/19/2026 13:20 PDT] 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT), Up By 100% ($14.06) After BUYINS.NET SqueezeTrigger Report Released on Monday, August 17th 2026 at a Price of $14.06.
• [08/17/2026 11:07 PDT] FDMT SqueezeTrigger Price is $0.00. There is $0 That Short Sellers Still Need To Cover.
• [08/17/2026 10:29 PDT] 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT), Up By 100% ($11.14) From $11.14 After BUYINS.NET Report Predicted Stock Would Go Up Due To Bullish Conditions
• [08/11/2026 06:16 PDT] FDMT Expected to Trade Up Short Term
• [08/05/2026 06:59 PDT] FDMT, Expected to Trade Lower After Bearish Insider Trading
• [07/30/2026 06:13 PDT] FDMT Expected to Trade Down Short Term
• [07/21/2026 06:43 PDT] FDMT Expected to Trade Up After Bullish Patterns Develop
• [07/21/2026 04:38 PDT] FDMT Expected to Trade Up Short Term
• [07/15/2026 06:54 PDT] FDMT, Expected to Trade Lower After Bearish Insider Trading
• [07/13/2026 10:29 PDT] 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT), Down By 100% ($13.26) From $13.26 After BUYINS.NET Report Predicted Stock Would Go Down Due To Bearish Conditions
• [07/06/2026 06:49 PDT] FDMT Expected to Trade Down After Bearish Patterns Develop
• [07/01/2026 06:39 PDT] FDMT Expected to Trade Up After Bullish Patterns Develop
• [06/30/2026 07:46 PDT] FDMT Expected to Trade Up After Bullish Patterns Develop
• [06/24/2026 06:21 PDT] FDMT, Expected to Trade Lower After Bearish Insider Trading
• [06/24/2026 06:12 PDT] FDMT Expected to Trade Up After Bullish Patterns Develop
• [06/23/2026 15:33 PDT] 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT), Up By 100% ($10.42) From $10.42 After BUYINS.NET Report Predicted Stock Would Go Up Due To Bullish Conditions
• [06/23/2026 05:32 PDT] FDMT Expected to Trade Up Short Term
• [06/22/2026 14:36 PDT] 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT), Up By 100% ($8.84) From $8.84 After BUYINS.NET Report Predicted Stock Would Go Up Due To Bullish Conditions